J&J leads the way in showing drug price information on screen

Johnson & Johnson (NYSE: JNJ) subsidiary Janssen has revealed that it will begin including drug price information in its direct-to-consumer (DTC) product advertising later in the year.

Billed as “additional transparency that would enable patients to make more informed decisions,” the move follows US trade group PhRMA’s revised advertising principles, a reaction to the President’s American Patients First Blueprint.

Janssen says it will start with information about the cost of its most frequently prescribed medicines, including both the list price and potential patient out-of-pocket costs.